Biotie Therapies Selects Bracket's CDR System for Phase II Parkinson's Trial
Bracket announced that Biotie Therapies has selected its CDR System for use as the primary endpoint for their Phase II trial.
Bracket announced that Biotie Therapies, a specialized drug development company focusing on products for neurodegenerative and psychiatric disorders, has selected its CDR System for use as the primary endpoint for their Phase II trial of SYN120, an orally administered, dual 5HT6/5HT2a antagonist. SYN120 is in development for the treatment of Parkinson’s disease and other cognitive disorders.
The CDR System, a computerized cognitive testing method, has been used successfully in over 25 therapeutic trials including, but not limited to, Parkinson’s Disease, Alzheimer’s Disease and Mild Cognitive Impairment. It assesses the major domains of cognitive function that are vulnerable to aging, fatigue, disease, pathology, trauma, diet and pharmaceuticals.
Read the full release
here
.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
